Literature DB >> 6999005

The mechanism of the carbohydrate intolerance of cirrhosis.

J Proietto, F P Alford, F J Dudley.   

Abstract

Cirrhosis of the liver is frequently associated with carbohydrate intolerance but it is unknown whether this intolerance is due to increased hepatic glucose production (HGP), decreased glucose utilization, or both. HGP and the MCR of glucose [(MCR)G] were measured at steady state, basally and during an infusion of insulin (25 mU/kg x h) and glucose (11 mumol/kg x min), in 11 cirrhotics and 8 controls using the technique of a primed constant infusion of [3H]3-glucose. HGP was also estimated at nonsteady state during an infusion of glucagon (8 ng/kg x min). Basal HGP was significantly lower in cirrhotics compared to controls (10.2 +/- 0.6 vs. 13.2 +/- 0.6 mumol/kg x min; P < 0.0025). During the insulin/glucose infusion, HGP was suppressed to the same degree in both groups [in controls by 83% (13.2 +/- 0.6 to 2.2 +/- 0.8 mumol/kg x min) and in cirrhotics by 87% (10.2 +/- 0.6 to 1.3 +/- 0.4 mumol/kg x min)]. After the glucagon infusion, HGP rose by a similar degree in cirrhotics and controls. In contrast, basal (MCR)G was significantly lower in the nondiabetic cirrhotics (2.1 +/- .02 ml/kg x min; P < 0.005) and diabetic cirrhotics (1.2 +/- 0.2 ml/kg x min; P < 0.0005) compared to that in the control subjects (2.8 +/- 0.2 ml/kg x min). Moreover, there was a highly significant (P < 0.001) negative correlation between basal (MCR)G and the fasting glucose level (r = 0.82), and the degree of glucose intolerance as expressed by the 2-h glucose level determined by the oral glucose tolerance test (r = 0.87). It is concluded that the glucose intolerance of cirrhosis is due to a defect in peripheral glucose utilization.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6999005     DOI: 10.1210/jcem-51-5-1030

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Effects of collateral vessel occlusion on oral glucose tolerance test in liver cirrhosis.

Authors:  N Tanabe; M Ishii; Y Sato; T Akahane; N Kobayashi; H Gama; T Iwasaki; T Toyota
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

Review 2.  Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: the role of skeletal muscle glucose uptake and hepatic glucose production in the development of hyperglycaemia. A critical comment.

Authors:  H Beck-Nielsen; O Hother-Nielsen; A Vaag; F Alford
Journal:  Diabetologia       Date:  1994-02       Impact factor: 10.122

3.  Insulin resistance in porphyria cutanea tarda.

Authors:  F Calcinaro; G Basta; P Lisi; C Cruciani; M Pietropaolo; F Santeusanio; A Falorni; R Calafiore
Journal:  J Endocrinol Invest       Date:  1989-06       Impact factor: 4.256

4.  Insulin resistance in liver cirrhosis. Positron-emission tomography scan analysis of skeletal muscle glucose metabolism.

Authors:  O Selberg; W Burchert; J vd Hoff; G J Meyer; H Hundeshagen; E Radoch; H J Balks; M J Müller
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  Glycerol clearance in alcoholic liver disease.

Authors:  D G Johnston; K G Alberti; R Wright; P G Blain
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

6.  In vivo insulin action in hepatocellular and cholestatic liver cirrhosis.

Authors:  N Barzilai; P Cohen; E Karnieli; R Enat; O Epstein; J Owen; N McIntyre
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

7.  Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis.

Authors:  G Marchesini; G P Bianchi; G Forlani; A G Rusticali; D Patrono; M Capelli; M Zoli; P Vannini; E Pisi
Journal:  Dig Dis Sci       Date:  1987-10       Impact factor: 3.199

8.  Nature and quantity of fuels consumed in patients with alcoholic cirrhosis.

Authors:  O E Owen; V E Trapp; G A Reichard; M A Mozzoli; J Moctezuma; P Paul; C L Skutches; G Boden
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

9.  The effect of liver microsomal enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man.

Authors:  J T Lahtela; B Gachalyi; S Eksymä; A Hämäläinen; E A Sotaniemi
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

10.  Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients.

Authors:  Y T Kruszynska; D S Harry; R N Bergman; N McIntyre
Journal:  Diabetologia       Date:  1993-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.